Assuntos
Infecções por HIV , Transmissão Vertical de Doenças Infecciosas , Humanos , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/estatística & dados numéricos , Infecções por HIV/transmissão , Recém-Nascido , Feminino , Gravidez , Lactente , Complicações Infecciosas na GravidezAssuntos
Marca-Passo Artificial , Humanos , Marca-Passo Artificial/efeitos adversos , Marca-Passo Artificial/microbiologia , Masculino , Endocardite Bacteriana/microbiologia , Endocardite Bacteriana/tratamento farmacológico , Idoso , Endocardite/microbiologia , Antibacterianos/uso terapêutico , Infecções Relacionadas à Prótese/microbiologia , Infecções Relacionadas à Prótese/tratamento farmacológicoRESUMO
Evidence-based interventions for Staphylococcus aureus bacteremia (SAB) are well known, but it is unclear how they are implemented among patients with injection drug use-associated (IDU) SAB. Of 46 patients with IDU-SAB identified, all received high-quality SAB management; however, few received appropriate recognition or treatment of their underlying substance use disorder.
RESUMO
BACKGROUND: Iron deficiency is associated with reduced functional capacity and increased mortality in patients with heart failure with reduced ejection fraction (HFrEF). Correction of iron deficiency in HFrEF patients with the use of intravenous iron improves symptoms, quality of life, and exercise performance. Whether oral iron improves iron stores in HFrEF patients is unknown. We conducted a retrospective study to assess the efficacy of oral iron supplementation in iron-deficient HFrEF patients. METHODS AND RESULTS: Iron-deficient HFrEF patients with a record of oral iron supplementation and iron studies before and â¼180 days after supplementation were identified. Iron deficiency was defined as ferritin <100 ng/mL or as ferritin 100-300 ng/mL with transferrin saturation (Tsat) <20%. Spearman correlation was performed to assess for treatment responsiveness. In 105 patients, ferritin (from median 39 ng/mL to 75 ng/mL), Tsat (from 10% to 21%), iron (from 34 µg/dL to 69 µg/dL), and hemoglobin (from 10.4 g/dL to 11.6 g/dL) values increased (P < .0001), whereas total iron-binding capacity decreased (from 343 to 313 µg/dL; P = .0007) at 164 days after initiation of oral iron supplementation. CONCLUSIONS: In this retrospective study, oral iron supplementation improved iron stores similarly to previously reported results with the use of intravenous iron repletion in HFrEF patients, suggesting that oral iron merits prospective evaluation as an intervention strategy in HFrEF.
